Eli Lilly and Company
LLY
$1,017.97
-$34.02-3.23%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 44.70% | 45.41% | 36.83% | 36.38% | 32.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.70% | 45.41% | 36.83% | 36.38% | 32.00% |
| Cost of Revenue | 31.29% | 29.24% | 23.42% | 25.81% | 18.86% |
| Gross Profit | 47.79% | 49.23% | 40.03% | 38.99% | 35.44% |
| SG&A Expenses | 29.09% | 36.34% | 33.09% | 27.66% | 23.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.71% | 27.28% | 23.18% | 21.42% | 20.00% |
| Operating Income | 74.27% | 77.02% | 61.44% | 66.94% | 57.96% |
| Income Before Tax | 102.93% | 121.70% | 87.55% | 79.87% | 93.45% |
| Income Tax Expenses | 143.59% | 129.76% | 85.74% | 75.28% | 59.03% |
| Earnings from Continuing Operations | 94.90% | 119.98% | 87.95% | 80.93% | 102.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 94.90% | 119.98% | 87.95% | 80.93% | 102.08% |
| EBIT | 74.27% | 77.02% | 61.44% | 66.94% | 57.96% |
| EBITDA | 68.52% | 70.63% | 56.84% | 61.08% | 52.72% |
| EPS Basic | 95.78% | 120.64% | 88.34% | 81.01% | 102.08% |
| Normalized Basic EPS | 73.89% | 80.06% | 63.59% | 69.84% | 61.00% |
| EPS Diluted | 95.96% | 121.03% | 88.57% | 81.17% | 102.12% |
| Normalized Diluted EPS | 74.09% | 80.31% | 63.55% | 69.68% | 60.77% |
| Average Basic Shares Outstanding | -0.40% | -0.28% | -0.13% | -0.01% | 0.04% |
| Average Diluted Shares Outstanding | -0.52% | -0.40% | -0.09% | 0.07% | 0.18% |
| Dividend Per Share | 15.38% | 15.31% | 15.23% | 15.14% | 15.04% |
| Payout Ratio | -0.41% | -0.48% | -0.39% | -0.36% | -0.43% |